MétaCan
Menu
Back to cohort
Record W4403667780 · doi:10.1016/j.clml.2024.10.012

First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline Consortium

2024· review· en· W4403667780 on OpenAlexafffundabout
Sahar Khan, Debra Bergstrom, Julie Anne Côté, Rami Kotb, Richard LeBlanc, Martha Louzada, Hira Mian, Ibraheem Othman, Gabriele Colasurdo, Alissa Visram

Bibliographic record

VenueClinical Lymphoma Myeloma & Leukemia · 2024
Typereview
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsUniversity of OttawaUniversity of ManitobaJuravinski Cancer CentreMcMaster UniversitySaskatchewan Science CentreLondon Health Sciences CentreUniversité de MontréalWestern UniversityGLS Industries (Canada)Hôpital Maisonneuve-RosemontOttawa HospitalSaskatchewan Cancer AgencyWindsor Regional HospitalCancerCare ManitobaCentre hospitalier universitaire de QuébecMemorial University of Newfoundland
FundersHamilton Health SciencesCelgeneLeukemia and Lymphoma SocietySanofiAmgenPfizerBristol-Myers Squibb
KeywordsMedicineGuidelineMultiple myelomaFamily medicineIntensive care medicineInternal medicineOncologyPathology

Abstract

fetched live from OpenAlex

The availability of effective therapies for multiple myeloma (MM) has sparked debate on the role of first line autologous stem cell transplantation (ASCT), particularly in standard-risk patients. However, treatment for individuals with high-risk disease continues to display suboptimal outcomes. With novel therapies used earlier, practice is changing rapidly in the field of MM. Presently, quadruplet induction therapy incorporating an anti-CD38 monoclonal antibody to a proteasome inhibitor and an immunomodulatory drug prior to ASCT followed by maintenance therapy stands as the foremost strategy for attaining deep and sustained responses in transplant eligible MM (TEMM). This Canadian Consensus Guideline Consortium (CGC) proposes consensus recommendations for the first line treatment of TEMM. To address the needs of physicians and people diagnosed with MM, this document focuses on ASCT eligibility, induction therapy, mobilization and collection, conditioning, consolidation, and maintenance therapy, as well as, high-risk populations, management of adverse events, assessment of treatment response, and monitoring for disease relapse. The CGC will periodically review the recommendations herein and update as necessary.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.009
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.990
Threshold uncertainty score0.460

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.009
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.003
Bibliometrics0.0040.004
Science and technology studies0.0010.001
Scholarly communication0.0020.001
Open science0.0040.001
Research integrity0.0030.003
Insufficient payload (model declined to judge)0.0060.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.103
GPT teacher head0.409
Teacher spread0.306 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2024
Admission routes3
Has abstractyes

Explore more

Same venueClinical Lymphoma Myeloma & LeukemiaSame topicMultiple Myeloma Research and TreatmentsFrench-language works237,207